Buprenorphine

Major

Buprenorphine Chlorthalidone Hemiclor Explained Reduced efficacy of diuretics Details Buprenorphine Chlorzoxazone Lorzone Explained Enhanced neuromuscular blocking action and an increased risk of respiratory depression and CNS depression Details Buprenorphine Cimetidine Tagamet Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Ciprofloxacin Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Citalopram Celexa Explained An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Clarithromycin Biaxin Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Clemastine Clemasz Explained An increased risk of paralytic ileus Details Buprenorphine Clidinium Explained An increased risk of paralytic ileus Details Buprenorphine Clobazam Onfi Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Clofazimine Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Clomipramine Anafranil Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome, an increased risk of paralytic ileus and a... Details Buprenorphine Clonazepam Klonopin Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Clopamide Explained Reduced efficacy of diuretics Details Buprenorphine Clopidogrel Plavix Reduced efficacy of clopidogrel Details Buprenorphine Clorazepate Tranxene Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Clothiapine Explained Increased risk of cardiac arrhythmias Details Buprenorphine Cloxazolam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Clozapine Clozaril Explained An increased risk of QT interval prolongation, an increased risk of CNS and respiratory depression and an increased risk of paraly... Details Buprenorphine Cobicistat Tybost Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Cocaine Goprelto Explained An increased risk of serotonin syndrome Details Buprenorphine Codeine Tuzistra XR® (as a combination product containing Chlorpheniramine, Codeine) Explained Reduced analgesic effect and/or precipitation of withdrawal symptoms, an increased risk of serotonin syndrome and an increased ris... Details Buprenorphine Conivaptan Vaprisol Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Crizotinib Xalkori Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Cyclobenzaprine Amrix Explained An increased risk of serotonin syndrome, an increased risk of QT interval prolongation, an increased risk of CNS and respiratory d... Details Buprenorphine Cyclopenthiazide Explained Reduced efficacy of diuretics Details Buprenorphine Cyclopentolate Cyclogyl Explained An increased risk of paralytic ileus Details Buprenorphine Cyclosporine Atopica Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Cyclothiazide Explained Reduced efficacy of diuretics Details Buprenorphine Cyproheptadine Explained An increased risk of paralytic ileus and an increased risk of CNS depression Details Buprenorphine Dabrafenib Tafinlar Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation Details Buprenorphine Dantrolene Dantrium Explained Enhanced neuromuscular blocking action and an increased risk of respiratory depression and CNS depression Details Buprenorphine Daridorexant Explained An increased risk CNS depression Details Buprenorphine Darifenacin Enablex Explained An increased risk of paralytic ileus Details Buprenorphine Darunavir Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Dasatinib Phyrago An increased risk of QT interval prolongation Details Buprenorphine Degarelix Firmagon Explained An increased risk of QT interval prolongation Details Buprenorphine Delamanid Explained An increased risk of QT interval prolongation Details Buprenorphine Delavirdine Rescriptor® Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Delorazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Desflurane Suprane Explained An increased risk of QT interval prolongation, reduced desflurane (MAC) exposure needed to produce anesthesia Details